Brenig
4 employees on LinkedIn · 4 known investors
Find your way into Brenig
2,154 people in our graph share verified history with the Brenig team — schools, employers, funds. One of them is your warm intro.
Dominic Jacquessonunlockedknows Iain Dukes · together at University of Oxford (overlapped)
knows the team · via NYU School of Medicine
×3knows the team · via McKinsey & Company
knows the team · via University of Pennsylvania
×3knows the team · via University of Leeds
×3knows the team · via University of Bath
Brenig Therapeutics is a biotechnology company developing small-molecule therapies for Parkinson's disease and other neurodegenerative disorders, using AI-driven drug discovery. Its pipeline includes BT-267, a brain-penetrant LRRK2 inhibitor, and BT-409, an NLRP3 inflammasome inhibitor.
Founders & leadership
MM
Megan McGillinChief Executive OfficerMegan McGill is a physician and radiologist who has held strategy and business development roles at gene therapy and genetic medicines companies, including Regenxbio and Ultragenyx. She is CEO of Brenig Therapeutics.
ID
NS
TD
Tien DaminChief Medical OfficerTien Dam is an academic clinician and drug development researcher with experience in neuroscience across pharmaceutical and biotech companies, where he has led programs in neurological and neuropsychiatric indications including Parkinson's disease, movement disorders, and psychiatric conditions.
Investors · 4
Frequently asked questions
- What does Brenig do?
- Brenig Therapeutics is a biotechnology company developing small-molecule therapies for Parkinson's disease and other neurodegenerative disorders, using AI-driven drug discovery. Its pipeline includes BT-267, a brain-penetrant LRRK2 inhibitor, and BT-409, an NLRP3 inflammasome inhibitor.
- Who are Brenig's investors?
- Brenig's investors include New Enterprise Associates (NEA), OrbiMed, BGV, Torrey Pines Investment.